Understanding the tumor microenvironment for effective immunotherapy

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · see citing works

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works

Understanding the tumor immune microenvironment (TIME) for effective therapy

Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · see citing works

New functions for the matrix metalloproteinases in cancer progression

Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108 · see citing works

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461 · see citing works

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · see citing works

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · see citing works

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

Reactive oxygen species (ROS) as pleiotropic physiological signalling agents

Sies, H., & Jones, D. P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0230-3 · Cited by 5,335 · see citing works

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · see citing works

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1× · see citing works

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works

Fibroblasts in cancer

Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · see citing works

The biology and function of fibroblasts in cancer

Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366 · see citing works

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1× · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · see citing works

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · see citing works

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,414 · see citing works

Fundamentals of Cancer Metabolism

DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · see citing works

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · see citing works

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · see citing works

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works

NF-κB, inflammation, immunity and cancer: coming of age

Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679 · see citing works

Hallmarks of Cellular Senescence

Hernandez-Segura, A., Nehme, J., & Demaria, M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.001 · Cited by 2,605 · see citing works

Dendritic cells in cancer immunology and immunotherapy

Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,594 · see citing works

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503 · see citing works

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,492 · see citing works

Chimeric Antigen Receptor Therapy

June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,355 · see citing works

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · see citing works

Regulation and Function of the PD-L1 Checkpoint

Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,187 · see citing works

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · see citing works

Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress

Sies, H. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.035 · Cited by 2,148 · see citing works

T Cell Activation

Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144 · see citing works

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · see citing works

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053 · see citing works

The extracellular matrix modulates the hallmarks of cancer

Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO Reports · doi:10.15252/embr.201439246 · Cited by 2,014 · see citing works

Turning foes to friends: targeting cancer-associated fibroblasts

Chen, X., & Song, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,884 · see citing works

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857 · see citing works

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · see citing works

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759 · see citing works

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635 · see citing works

Immune evasion in cancer: mechanistic basis and therapeutic strategies

Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625 · see citing works

CD4+ T cell help in cancer immunology and immunotherapy

Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585 · see citing works

Immune-related adverse events of checkpoint inhibitors

Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,447 · see citing works

Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy

Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441 · cited 2× · see citing works

CD8+ T cell states in human cancer: insights from single-cell analysis

van der Leun, A. M., Thommen, D. S., & Schumacher, T. N. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-019-0235-4 · Cited by 1,439 · see citing works

CCR7 and its ligands: balancing immunity and tolerance

Förster, R., Davalos-Misslitz, A. C., & Rot, A. (2008) · Nature Reviews Immunology · doi:10.1038/nri2297 · Cited by 1,410 · see citing works

Emerging landscape of oncogenic signatures across human cancers

Ciriello, G., Miller, M. L., Aksoy, B. A., Şenbabaoğlu, Y., Schultz, N. D., & Sander, C. (2013) · Nature Genetics · doi:10.1038/ng.2762 · Cited by 1,382 · see citing works

Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing

Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · see citing works

Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C. B., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,358 · see citing works

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348 · cited 1× · see citing works

Perforin and granzymes: function, dysfunction and human pathology

Voskoboinik, I., Whisstock, J. C., & Trapani, J. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3839 · Cited by 1,327 · see citing works

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · see citing works

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger‐Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D. A., Vennapusa, B., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,277 · see citing works

Cellular Adaptation to Hypoxia through Hypoxia Inducible Factors and beyond

Lee, P., Chandel, N. S., & Simon, M. C. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0227-y · Cited by 1,272 · see citing works

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191 · see citing works

Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

Salmon, H., Idoyaga, J., Rahman, A. H., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M. N., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,187 · see citing works

Natural Killer Cells: Development, Maturation, and Clinical Utilization

Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150 · see citing works

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · see citing works

Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma

Li, H., van der Leun, A. M., Yofe, I., Lubling, Y., Gelbard-Solodkin, D., van Akkooi, A. C. J., van den Braber, M., Rozeman, E. A., Haanen, J. B. A. G., Blank, C. U., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.043 · Cited by 1,101 · see citing works

Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer

Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095 · see citing works

Targeting natural killer cells in cancer immunotherapy

Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,060 · see citing works

Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction

Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009 · see citing works

Natural killer cells and other innate lymphoid cells in cancer

Chiossone, L., Dumas, P., Vienne, M., & Vivier, É. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,003 · see citing works

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000 · see citing works

Neutrophils support lung colonization of metastasis-initiating breast cancer cells

Wculek, S. K., & Malanchi, I. (2015) · Nature · doi:10.1038/nature16140 · Cited by 996 · see citing works

The epigenetic landscape of T cell exhaustion

Sen, D. R., Kaminski, J., Barnitz, R. A., Kurachi, M., Gerdemann, U., Yates, K. B., Tsao, H.-W., Godec, J., LaFleur, M. W., Brown, F. D., et al. (2016) · Science · doi:10.1126/science.aae0491 · Cited by 986 · see citing works

In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer

Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6147 · Cited by 953 · see citing works

Effector and Memory CTL Differentiation

Williams, M. A., & Bevan, M. J. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141548 · Cited by 942 · see citing works

Targeting tumor-associated macrophages in cancer

Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933 · see citing works

Memory CD8 T-Cell Differentiation during Viral Infection

Wherry, E. J., & Ahmed, R. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5535-5545.2004 · Cited by 858 · see citing works

Tumor-associated macrophages: from basic research to clinical application

Yang, L., & Zhang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0430-2 · Cited by 847 · see citing works

Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell–dendritic cell interaction

Castellino, F., Huang, A. Y.-C., Altan-Bonnet, G. Y., Stoll, S., Scheinecker, C., & Germain, R. N. (2006) · Nature · doi:10.1038/nature04651 · Cited by 847 · see citing works

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression

Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 846 · see citing works

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

Tay, R. E., Richardson, E. K., & Toh, H. C. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 801 · see citing works

The role of cellular reactive oxygen species in cancer chemotherapy

Yang, H., Villani, R. M., Wang, H., Simpson, M. J., Roberts, M. S., Tang, M., & Liang, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0909-x · Cited by 794 · see citing works

The future of cancer immunotherapy: microenvironment-targeting combinations

Murciano‐Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 753 · see citing works

T-helper-1-cell cytokines drive cancer into senescence

Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720 · see citing works

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies

Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 706 · see citing works

Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells

De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687 · see citing works

Mast cells as sources of cytokines, chemokines, and growth factors

Mukai, K., Tsai, M. M., Saito, H., & Galli, S. J. (2018) · Immunological Reviews · doi:10.1111/imr.12634 · Cited by 687 · see citing works

TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway

Viel, S., Marçais, A., Souza-Fonseca-Guimarães, F., Loftus, R. M., Rabilloud, J., Grau, M., Degouve, S., Djebali, S., Sanlaville, A., Charrier, E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aad1884 · Cited by 675 · see citing works

CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions

Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043208 · Cited by 659 · see citing works

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells

Gao, Y., Souza-Fonseca-Guimarães, F., Bald, T., Ng, S. S., Young, A., Ngiow, S. F., Rautela, J., Straube, J., Waddell, N., Blake, S. J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3800 · Cited by 654 · see citing works

Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors

Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653 · see citing works

Biology and regulation of IL-2: from molecular mechanisms to human therapy

Spolski, R., Li, P., & Leonard, W. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0046-y · Cited by 637 · see citing works

Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity

Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J. L., Ruhland, M. K., Kersten, K., Abushawish, M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 629 · see citing works

Clinical blockade of PD1 and LAG3 — potential mechanisms of action

Nguyen, L. T., & Ohashi, P. S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3790 · Cited by 621 · see citing works

Why are tumour blood vessels abnormal and why is it important to know?

Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604929 · Cited by 611 · see citing works

Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells

Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P., & Shields, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03347-0 · Cited by 578 · see citing works

The hallmarks of successful anticancer immunotherapy

Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575 · see citing works

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

Angell, H., & Galon, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.004 · Cited by 574 · see citing works

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

Ugel, S., Sanctis, F. D., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 563 · see citing works

In Vivo CD4 ⁺ T Cell Differentiation and Function: Revisiting the Th1/Th2 Paradigm

Ruterbusch, M., Pruner, K. B., Shehata, L., & Pepper, M. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-103019-085803 · Cited by 550 · see citing works

Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response

Mandal, R., Samstein, R. M., Lee, K.-W., Havel, J. J., Wang, H., Krishna, C., Sabio, E. Y., Makarov, V., Kuo, F., Blecua, P., et al. (2019) · Science · doi:10.1126/science.aau0447 · Cited by 549 · see citing works

The Extracellular Matrix Modulates the Metastatic Journey

Kai, F., Drain, A. P., & Weaver, V. M. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.03.026 · Cited by 537 · see citing works

RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues

Yizhak, K., Aguet, F., Kim, J., Hess, J. M., Kübler, K., Grimsby, J., Frazer, R., Zhang, H., Haradhvala, N. J., Rosebrock, D., et al. (2019) · Science · doi:10.1126/science.aaw0726 · Cited by 500 · see citing works

T-bet: a bridge between innate and adaptive immunity

Lazarevic, V., Glimcher, L. H., & Lord, G. M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3536 · Cited by 486 · cited 1× · see citing works

Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma

Prat, A., Navarro, A., Paré, L., Reguart, N., Galván, P., Pascual, T., Martínez, A., Nuciforo, P., Comerma, L., Alos, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3556 · Cited by 455 · see citing works

Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer

Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455 · see citing works

The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective

Galon, J., Fridman, W. H., & Pagès, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4806 · Cited by 447 · see citing works

Therapeutic targeting of trained immunity

Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A., & Netea, M. G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0025-4 · Cited by 446 · see citing works

Demonstration That Human Mast Cells Arise From a Progenitor Cell Population That Is CD34+, c-kit+, and Expresses Aminopeptidase N (CD13)

Kirshenbaum, A. S., Goff, J. P., Semere, T., Foster, B. A., Scott, L. M., & Metcalfe, D. D. (1999) · Blood · doi:10.1182/blood.v94.7.2333.419k30_2333_2342 · Cited by 420 · see citing works

CAR-T cells: the long and winding road to solid tumors

D’Aloia, M. M., Zizzari, I. G., Sacchetti, B., Pierelli, L., & Alimandi, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0278-6 · Cited by 403 · see citing works

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

Klempner, S. J., Fabrizio, D. A., Bane, S., Reinhart, M. L., Peoples, T., Ali, S. M., Sokol, E. S., Frampton, G. M., Schrock, A. B., Anhorn, R., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0244 · Cited by 398 · see citing works

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

Mayoux, M., Roller, A., Pulko, V., Sammicheli, S., Chen, S., Sum, E., Jost, C., Fransen, M. F., Buser, R. B., Kowanetz, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7431 · Cited by 394 · see citing works

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment

Young, A., Ngiow, S. F., Gao, Y., Patch, A., Barkauskas, D. S., Messaoudene, M., Lin, G., Coudert, J. D., Stannard, K. A., Zitvogel, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2826 · Cited by 393 · see citing works

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 385 · see citing works

The Immunoscore: Colon Cancer and Beyond

Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R., & Galon, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1851 · Cited by 384 · see citing works

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

Cohen, C. J., Gartner, J. J., Horovitz‐Fried, M., Shamalov, K., Trebska-McGowan, K., Bliskovsky, V. V., Parkhurst, M. R., Ankri, C., Prickett, T. D., Crystal, J. S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82416 · Cited by 374 · see citing works

Expression profiling of constitutive mast cells reveals a unique identity within the immune system

Dwyer, D. F., Barrett, N. A., & Austen, K. F. (2016) · Nature Immunology · doi:10.1038/ni.3445 · Cited by 365 · see citing works

Driver and Passenger Mutations in Cancer

Pon, J. R., & Marra, M. A. (2014) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040312 · Cited by 356 · see citing works

Immunoregulation by members of the TGFβ superfamily

Chen, W., & ten Dijke, P. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.112 · Cited by 347 · see citing works

Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers

Pearce, O. M. T., Delaine‐Smith, R. M., Maniati, E., Nichols, S., Wang, J., Böhm, S., Rajeeve, V., Ullah, D., Chakravarty, P., Jones, R. R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0284 · Cited by 339 · see citing works

Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms

Kim, I. S., Gao, Y., Welte, T., Wang, H., Liu, J., Janghorban, M., Sheng, K., Niu, Y., Goldstein, A., Zhao, N., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0373-7 · Cited by 334 · see citing works

Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement

Liu, J., Chen, Q., Feng, L., & Liu, Z. (2018) · Nano Today · doi:10.1016/j.nantod.2018.06.008 · Cited by 329 · see citing works

Transcriptional regulation of granulocyte and monocyte development

Friedman, A. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205324 · Cited by 325 · see citing works

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

Liu, Y., Zugazagoitia, J., Ahmed, F. S., Henick, B. S., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1040 · Cited by 322 · see citing works

Neutrophils: key mediators of tumour angiogenesis

Tazzyman, S. J., Lewis, C. E., & Murdoch, C. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00641.x · Cited by 319 · see citing works

Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma

Czystowska, M., Sosnowska, A., Nowis, D., Ramji, K., Szajnik, M. E., Chlebowska, J., Wolińska, E., Gaj, P., Grażul, M., Pilch, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10979-3 · Cited by 315 · see citing works

Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence

Camus, M., Tosolini, M., Mlecnik, B., Pagès, F., Kirilovsky, A., Berger, A., Costes, A., Bindea, G., Charoentong, P., Bruneval, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2654 · Cited by 307 · see citing works

ROS homeostasis and metabolism: a critical liaison for cancer therapy

Kim, J., Kim, J., & Bae, J. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.119 · Cited by 295 · see citing works

Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Non–Small-Cell Lung Cancer

Swinson, D., Jones, J. L., Richardson, D. L., Wykoff, C. C., Turley, H., Pastorek, J., Taub, N. A., Harris, A. L., & O'Byrne, K. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.132 · Cited by 288 · see citing works

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

Ock, C.-Y., Keam, B., Kim, S., Lee, J., Kim, M., Kim, T. M., Jeon, Y. K., Kim, D., Chung, D. H., & Heo, D. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2834 · Cited by 265 · see citing works

Neutrophil-derived chemokines on the road to immunity

Tecchio, C., & Cassatella, M. A. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.04.003 · Cited by 261 · see citing works

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0193 · Cited by 248 · see citing works

Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer

Singhal, S. K., Stadanlick, J. E., Annunziata, M. J., Rao, A. S., Bhojnagarwala, P. S., O’Brien, S., Moon, E. K., Cantu, E., Danet-Desnoyers, G. A., Ra, H.-J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat1500 · Cited by 244 · see citing works

Migratory CD11b + conventional dendritic cells induce T follicular helper cell–dependent antibody responses

Krishnaswamy, J. K., Gowthaman, U., Zhang, B., Mattsson, J., Szeponik, L., Liu, D., Wu, R., White, T. L., Calabrό, S., Xu, L., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aam9169 · Cited by 238 · see citing works

Hallmarks of response to immune checkpoint blockade

Cogdill, A. P., Andrews, M. C., & Wargo, J. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.136 · Cited by 238 · see citing works

Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts

Fumet, J.-D., Truntzer, C., Yarchoan, M. M., & Ghiringhelli, F. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.038 · Cited by 237 · see citing works

CRISPR screen in regulatory T cells reveals modulators of Foxp3

Cortez, J. T., Montauti, E. I., Shifrut, E., Gatchalian, J., Zhang, Y., Shaked, O., Xu, Y., Roth, T. L., Simeonov, D. R., Zhang, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2246-4 · Cited by 237 · see citing works

Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis

Marshall, E. A., Ng, K. W., Kung, S. H. Y., Conway, E. M., Martínez, V. D., Halvorsen, E. C., Rowbotham, D. A., Vucic, E. A., Plumb, A. W., Becker‐Santos, D. D., et al. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0551-1 · Cited by 230 · see citing works

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., Håkansson, L., Hanks, B. A., Karanikas, V., Khleif, S. N., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0243-4 · Cited by 229 · see citing works

Tcf1 and Lef1 transcription factors establish CD8+ T cell identity through intrinsic HDAC activity

Xing, S., Li, F., Zeng, Z., Zhao, Y., Yu, S., Shan, Q., Li, Y., Phillips, F. C., Maina, P. K., Qi, H. H., et al. (2016) · Nature Immunology · doi:10.1038/ni.3456 · Cited by 226 · see citing works

IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis

Bishnupuri, K. S., Alvarado, D. M., Khouri, A. N., Shabsovich, M., Chen, B., Dieckgraefe, B. K., & Ciorba, M. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0668 · Cited by 212 · see citing works

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

Thompson, J. A. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0047 · Cited by 209 · see citing works

Extracellular Acidic pH Activates the Sterol Regulatory Element-Binding Protein 2 to Promote Tumor Progression

Kondo, A., Yamamoto, S., Nakaki, R., Shimamura, T., Hamakubo, T., Sakai, J., Kodama, T., Yoshida, T., Aburatani, H., & Osawa, T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.006 · Cited by 209 · see citing works

Human Mast Cell Proteome Reveals Unique Lineage, Putative Functions, and Structural Basis for Cell Ablation

Plum, T., Wang, X., Rettel, M., Krijgsveld, J., Feyerabend, T. B., & Rodewald, H.-R. (2020) · Immunity · doi:10.1016/j.immuni.2020.01.012 · Cited by 194 · see citing works

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

Xiao, G., Jin, L.-L., Liu, C., Wang, Y., Meng, Y.-M., Zhou, Z., Chen, J., Yu, X.-J., Zhang, Y., Xu, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0784-9 · Cited by 182 · see citing works

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers

Fultang, L., Panetti, S., Ng, M. H. L., Collins, P. J., Graef, S., Rizkalla, N., Booth, S., Lenton, R., Noyvert, B., Shannon-Lowe, C. D., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.025 · Cited by 169 · see citing works

Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway

Lv, Y.-P., Zhao, Y., Wang, X., Chen, N., Mao, F., Teng, Y., Wang, T., Peng, L., Zhang, J., Cheng, P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0530-3 · Cited by 165 · see citing works

Treg(s) in Cancer: Friends or Foe?

Wolf, D. G. F., Sopper, S., Pircher, A., Gastl, G. A., & Wolf, A. M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25016 · Cited by 153 · see citing works

The Role of the Tumor Microenvironment in Regulating AngiogenesisPreprint

Watnick, R. S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006676 · Cited by 150 · see citing works

The opposing roles of CD 4+ T cells in anti‐tumour immunity

Ahrends, T., & Borst, J. G. (2018) · Immunology · doi:10.1111/imm.12941 · Cited by 138 · see citing works

Maximal T Cell–Mediated Antitumor Responses Rely upon CCR5 Expression in Both CD4+ and CD8+ T Cells

González-Martín, A., Gómez, L., Lustgarten, J., Mira, E., & Mañes, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1687 · Cited by 137 · see citing works

Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy

Morein, D., Erlichman, N., & Ben‐Baruch, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00952 · Cited by 135 · see citing works

Cellular and molecular mechanisms in cancer immune escape: a comprehensive review

Bhatia, A., & Kumar, Y. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.865519 · Cited by 134 · see citing works

Chemotherapy and immunotherapy: mapping the road ahead

Cook, A., Lesterhuis, W. J., Nowak, A. K., & Lake, R. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.003 · Cited by 130 · see citing works

Recruitment of CD103 + dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy

Williford, J., Ishihara, J., Ishihara, A., Mansurov, A., Hosseinchi, P., Marchell, T. M., Potin, L., Swartz, M. A., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1357 · Cited by 127 · see citing works

The Damaging Effect of Passenger Mutations on Cancer Progression

McFarland, C. D., Yaglom, J. A., Wojtkowiak, J. W., Scott, J. G., Morse, D. L., Sherman, M. Y., & Mirny, L. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-15-3283-t · Cited by 120 · see citing works

Carcinogenesis and Reactive Oxygen Species Signaling: Interaction of the NADPH Oxidase NOX1–5 and Superoxide Dismutase 1–3 Signal Transduction Pathways

Parascandolo, A., & Laukkanen, M. O. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7268 · Cited by 117 · see citing works

Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling

Zugazagoitia, J., Gupta, S., Liu, Y., Fuhrman, K. A., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0175 · Cited by 112 · see citing works

Tcf7 Is an Important Regulator of the Switch of Self-Renewal and Differentiation in a Multipotential Hematopoietic Cell Line

Wu, J. Q., Seay, M., Schulz, V., Hariharan, M., Tuck, D. P., Lian, J., Du, J., Shi, M., Ye, Z., Gerstein, M., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002565 · Cited by 107 · see citing works

Transcription factor Foxp1 regulates Foxp3 chromatin binding and coordinates regulatory T cell function

Konopacki, C., Pritykin, Y., Rubtsov, Y. P., Leslie, C. S., & Rudensky, A. Y. (2019) · Nature Immunology · doi:10.1038/s41590-018-0291-z · Cited by 102 · see citing works

Conformational coupling of integrin and Thy-1 regulates Fyn priming and fibroblast mechanotransduction

Fiore, V. F., Strane, P. W., Bryksin, A. V., White, E. S., Hagood, J. S., & Barker, T. H. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201505007 · Cited by 92 · see citing works

High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors

Marçais, A., Marotel, M., Degouve, S., Koenig, A., Fauteux‐Daniel, S., Drouillard, A., Schlums, H., Viel, S., Besson, L., Allatif, O., et al. (2017) · eLife · doi:10.7554/elife.26423 · Cited by 91 · see citing works

Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis

Yoon, H. H., Shi, Q., Heying, E. N., Murányi, A., Bredno, J., Ough, F., Djalilvand, A., Clements, J., Bowermaster, R., Liu, W.-W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1984 · Cited by 88 · see citing works

Harnessing Natural Killer Immunity in Metastatic SCLC

Best, S. A., Hess, J. B., Souza-Fonseca-Guimarães, F., Cursons, J., Kersbergen, A. J., Dong, X., Rautela, J., Hyslop, S. R., Ritchie, M. E., Davis, M. J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.008 · Cited by 84 · see citing works

Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer

Barr, M. P., Gray, S. G., Gately, K. A., Hams, E., Fallon, P. G., Davies, A. M., Richard, D. J., Pidgeon, G. P., & O'Byrne, K. J. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0310-8 · Cited by 81 · see citing works

Therapeutic blockade of activin-A improves NK cell function and antitumor immunity

Rautela, J., Dagley, L. F., de Oliveira, C. C., Schuster, I. S., Hediyeh-zadeh, S., Delconte, R. B., Cursons, J., Hennessy, R. J., Hutchinson, D. S., Harrison, C. A., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aat7527 · Cited by 79 · see citing works

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma

Wong, P. F., Wei, W., Gupta, S., Smithy, J. W., Zelterman, D. A., Kluger, H. M., & Rimm, D. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0675-0 · Cited by 73 · see citing works

Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment

Danelli, L., Frossi, B., Gri, G., Mion, F., Guarnotta, C., Bongiovanni, L., Tripodo, C., Mariuzzi, L., Marzinotto, S., Rigoni, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0102 · Cited by 72 · see citing works

ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells

Gallego‐Ortega, D., Ledger, A., Roden, D. L., Law, A. M. K., Magenau, A., Kikhtyak, Z., Cho, C., Allerdice, S. L., Lee, H. J., Valdés‐Mora, F., et al. (2015) · PLoS Biology · doi:10.1371/journal.pbio.1002330 · Cited by 72 · see citing works

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer

O'Callaghan, D., Rexhepaj, E., Gately, K., Coate, L., Delaney, D., O'Donnell, D., Kay, E., O'Connell, F., Gallagher, W., & O'Byrne, K. (2015) · European Respiratory Journal · doi:10.1183/13993003.00176-2014 · Cited by 68 · see citing works

Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma

Zhao, J., Hou, Y., Yin, C., Hu, J. R., Gao, T., Huang, X., Zhang, X., Xing, J., An, J., Wan, S., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1093-y · Cited by 60 · see citing works

Identification of responders to immune checkpoint therapy: Which biomarkers have the highest value?

Liebl, M. C., & Hofmann, T. G. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15992 · Cited by 58 · see citing works

Induction of DNMT3B by PGE2 and IL6 at Distant Metastatic Sites Promotes Epigenetic Modification and Breast Cancer Colonization

So, J. Y., Skrypek, N., Yang, H. H., Merchant, A. S., Nelson, G. W., Chen, W.-D. D., Ishii, H., Chen, J. M., Hu, G., Achyut, B. R., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3339 · Cited by 53 · see citing works

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yu, Y. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0581-0 · Cited by 50 · see citing works

Tumor Immuno-Environment in Cancer Progression and Therapy

Kaliński, P., & Talmadge, J. E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_1 · Cited by 46 · see citing works

Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy

Cha, Y. J., Park, E. J., Baik, S. H., Lee, K. Y., & Kang, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-48140-1 · Cited by 42 · see citing works

The dual role of mast cells in tumor fate

Ribatti, D., Tamma, R., & Enrico Crivellato, B. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.005 · Cited by 36 · see citing works

Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma

Liu, S., Bian, L., Liu, Z., Chen, Q., Sun, X.-S., Sun, R., Luo, D., Li, X. N., Xiao, B.-B., Yan, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000205 · Cited by 36 · see citing works

Regulation of CTL Infiltration Within the Tumor Microenvironment

Church, S., & Galon, J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_3 · Cited by 35 · see citing works

Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung

Tashima, Y., Kuwata, T., Yoneda, K., Hirai, A., Mori, M., Kanayama, M., Imanishi, N., Kuroda, K., Ichiki, Y., & Tanaka, F. (2020) · Scientific Reports · doi:10.1038/s41598-019-57321-x · Cited by 34 · see citing works

Take lessons from cancer evolution to the clinic

Swanton, C. (2020) · Nature · doi:10.1038/d41586-020-01347-z · Cited by 26 · see citing works

ADAM17-dependent proteolysis of L-selectin promotes early clonal expansion of cytotoxic T cells

Mohammed, R. N., Wehenkel, S. C., Galkina, E., Yates, E.-K., Preece, G., Newman, A., Watson, H. A., Ohme, J., Bridgeman, J. S., Durairaj, R. R. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41811-z · Cited by 21 · see citing works

Fas/FasL signaling is critical for the survival of exhausted antigen-specific CD8+ T cells during tumor immune response

Yajima, T., Hoshino, K., Muranushi, R., Mogi, A., Onozato, R., Yamaki, E., Kosaka, T., Tanaka, S., Shirabe, K., Yoshikai, Y., et al. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.01.014 · Cited by 20 · see citing works

Drug development: Releasing the brakes

Weintraub, K. (2013) · Nature · doi:10.1038/504s6a · Cited by 19 · see citing works

Immune Checkpoint Inhibitors in Cancer Therapy

Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works

Defect Engineering in Nanocatalysts: From Design and Synthesis to Applications

Muhammad, P., Zada, A., Rashid, J., Hanif, S., Gao, Y., Li, C., Li, Y., Fan, K., & Wang, Y. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202314686 · Cited by 361 · see citing works

Targeting the Warburg Effect in Cancer: Where Do We Stand?

Barba, I., Carrillo-Bosch, L., & Seoane, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063142 · Cited by 248 · see citing works

The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Güven, D. C., Şahin, T. K., Erul, E., Rizzo, A., Ricci, A. D., Aksoy, S., & Yalçın, Ş. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1039121 · Cited by 214 · see citing works

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 196 · see citing works

Targeting of TAMs: can we be more clever than cancer cells?

Kzhyshkowska, J., Shen, J., & Larionova, I. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01232-z · Cited by 166 · see citing works

Immunotherapy in Breast Cancer

Dvir, K., Giordano, S. B., & Leone, J. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147517 · Cited by 162 · see citing works

Multimaterial 3D and 4D Bioprinting of Heterogenous Constructs for Tissue Engineering

Chen, A., Wang, W., Mao, Z., He, Y., Chen, S., Liu, G., Su, J. D., Feng, P., Shi, Y., Yan, C., et al. (2023) · Advanced Materials · doi:10.1002/adma.202307686 · Cited by 159 · see citing works

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition

Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 162 · see citing works

Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer

Liu, L., Mo, M., Chen, X., Chao, D., Zhang, Y., Chen, X., Wang, Y., Zhang, N., He, N., Yuan, X., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02647-8 · Cited by 91 · see citing works

Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma

Yang, Z., Tian, H., Chen, X., Li, B., Bai, G., Cai, Q., Xu, J., Guo, W., Wang, S., Peng, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52977-0 · Cited by 83 · see citing works

The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities

Garlisi, B., Lauks, S., Aitken, C., Ogilvie, L. M., Lockington, C., Petrik, D., Eichhorn, J. S., & Petrik, J. (2024) · Current Oncology · doi:10.3390/curroncol31070283 · Cited by 78 · see citing works

Targeting of the tumor microenvironment by curcumin

Fu, X., He, Y., Li, M., Huang, Z., & Najafi, M. (2021) · BioFactors · doi:10.1002/biof.1776 · Cited by 75 · see citing works

Metal-organic frameworks (MOFs) for phototherapy and synergistic phototherapy of cancer

Tong, P., Yang, J., Zhou, Y.-F., Tang, Y., Tang, M.-T., Zang, Y., Pan, Y., Dong, L., Tan, Y., Nam, K. T., et al. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216381 · Cited by 72 · see citing works

Crosstalk between metabolism and cell death in tumorigenesis

Yang, S., Hu, C., Chen, X., Tang, Y., Li, J., Yang, H., Yang, Y., Ying, B., Xiao, X., Li, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01977-1 · Cited by 71 · see citing works

Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity

Liu, T., Yang, K. Y., Chen, J., Qi, L.-M., Zhou, X., & Wang, P. (2023) · Biomolecules · doi:10.3390/biom13020326 · Cited by 63 · see citing works

Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer

Cheng, G., Zhang, F., Xing, Y., Hu, X., Zhang, H., Chen, S., Li, M., Peng, C., Ding, G., Zhang, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.893198 · Cited by 61 · see citing works

The interactions of docetaxel with tumor microenvironment

Gupta, R., Kadhim, M. M., Jalil, A. T., Alasheqi, M. Q., Alsaikhan, F., Mukhamedova, N. K., Ramírez‐Coronel, A. A., Jawhar, Z. H., Ramaiah, P., & Najafi, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110214 · Cited by 61 · see citing works

Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

Haider, M. A., Elsherbeny, A., Pittalà, V., Fallica, A. N., Alghamdi, M. A., Hussain, Z., Khoder, G., & Greish, K. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031853 · Cited by 59 · see citing works

Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions

Mandal, K., Barik, G. K., & Santra, M. K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02400-z · Cited by 65 · see citing works

Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products

Lafta, H. A., AbdulHussein, A. H., Al-Shalah, S. A. J., Alnassar, Y. S., Mohammed, N. M., Akram, S. M., Qasim, M. T., & Najafi, M. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230201145909 · Cited by 61 · see citing works

Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis

Shu, J., Jiang, J., & Zhao, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1177847 · Cited by 57 · see citing works

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55 · see citing works

Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment

Aden, D., Sureka, N., Zaheer, S., Chaurasia, J. K., & Zaheer, S. (2024) · Immunology · doi:10.1111/imm.13871 · Cited by 54 · see citing works

Peritumor tertiary lymphoid structures are associated with infiltrating neutrophils and inferior prognosis in hepatocellular carcinoma

Zhang, T., Lei, X., Jia, W., Li, J., Nie, Y., Mao, Z., Wang, Y., Tao, K., & Song, W. (2022) · Cancer Medicine · doi:10.1002/cam4.5227 · Cited by 53 · see citing works

Cuproptosis-related gene SLC31A1: prognosis values and potential biological functions in cancer

Qi, Y., Yao, Q., Li, X., Li, X., Zhang, W., & Qu, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-44681-8 · Cited by 51 · see citing works

Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance

Xiao, Y., Hassani, M., Moghaddam, M. B., Fazilat, A., Ojarudi, M., & Valilo, M. (2025) · Medical Oncology · doi:10.1007/s12032-025-02675-8 · Cited by 56 · see citing works

Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms

Zheng, J., Jiang, J., Pu, Y., Xu, T., Sun, J., Zhang, Q., He, L., & Liang, X. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1248421 · Cited by 48 · see citing works

Understanding the tumor microenvironment in head and neck squamous cell carcinoma

Sadeghirad, H., Shiravand, Y., Radfar, P., Ladwa, R., Perry, C., Han, X., Warkiani, M. E., Adams, M. N., Hughes, B. G. M., O'Byrne, K. J., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1397 · Cited by 47 · see citing works

Recent Advances in Nanoenzymes Based Therapies for Glioblastoma: Overcoming Barriers and Enhancing Targeted Treatment

Wang, L., Gu, M., Zhang, X., Kong, T., Liao, J., Zhang, D., & Li, J. (2025) · Advanced Science · doi:10.1002/advs.202413367 · Cited by 47 · see citing works

Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation

Bishoyi, A. K., Nouri, S., Hussen, A., Bayani, A., Khaksari, M. N., & Samarkhazan, H. S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01686-z · Cited by 45 · see citing works

Aggregable gold nanoparticles for cancer photothermal therapy

Wu, M., Xiao, Y., Wu, R., Lei, J., Li, T. X., & Zheng, Y. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00403e · Cited by 44 · see citing works

The Role of Circulating Biomarkers in Lung Cancer

Herath, S., Sadeghirad, H., Radfar, P., Ladwa, R., Warkiani, M. E., O'Byrne, K. J., & Kulasinghe, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.801269 · Cited by 44 · see citing works

Radiotherapy-activated tumor immune microenvironment: Realizing radiotherapy-immunity combination therapy strategies

Luo, H., Ma, W., Chen, Q., Yáng, Z., & Dai, Y. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102042 · Cited by 43 · see citing works

Multi‐omic and spatial dissection of immunotherapy response groups in non‐small cell lung cancer

Monkman, J. H., Kim, H., Mayer, A. T., Mehdi, A. M., Matigian, N., Cumberbatch, M., Bhagat, M., Ladwa, R., Mueller, S. N., Adams, M. N., et al. (2023) · Immunology · doi:10.1111/imm.13646 · Cited by 42 · see citing works

Advances in Targeted and Chemotherapeutic Strategies for Colorectal Cancer: Current Insights and Future Directions

Shaham, S. H., Vij, P., & Tripathi, M. K. (2025) · Biomedicines · doi:10.3390/biomedicines13030642 · Cited by 44 · see citing works

Modelling the tumor immune microenvironment for precision immunotherapy

Mackenzie, N. J., Nicholls, C., Templeton, A. R., Perera, O. M., Jeffery, P. L., Zimmermann, K., Kulasinghe, A., Kenna, T., Vela, I., Williams, E. D., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1400 · Cited by 41 · see citing works

A deep convolutional neural network for segmentation of whole-slide pathology images identifies novel tumour cell-perivascular niche interactions that are associated with poor survival in glioblastoma

Shirazi, A. Z., McDonnell, M. D., Fornaciari, E., Bagherian, N. S., Scheer, K. G., Samuel, M. S., Yaghoobi, M., Ormsby, R. J., Poonnoose, S. I., Tumes, D. J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01394-x · Cited by 40 · see citing works

Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy

Jin, Z., Sun, X., Wang, Y., Zhou, C., Yang, H., & Zhou, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018903 · Cited by 39 · see citing works

Recent Progress in Bio-Responsive Drug Delivery Systems for Tumor Therapy

Cong, X., Chen, J., & Xu, R. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.916952 · Cited by 38 · see citing works

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy

Sadeghirad, H., Liu, N., Monkman, J. H., Ma, N., Cheikh, B. B., Jhaveri, N., Tan, C. W., Warkiani, M. E., Adams, M. N., Nguyen, Q. H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1135489 · Cited by 35 · see citing works

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

Kamaraj, R., Ghosh, S., Das, S., Sen, S., Kumar, P. R., Majumdar, M., Dasgupta, R., Mukherjee, S., Das, S., Ghose, I., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00253 · Cited by 37 · see citing works

Emerging role of circulating tumor cells in immunotherapy

Rzhevskiy, A. S., Kapitannikova, A. Y., Malinina, P., Volovetsky, A. B., Es, H. A., Kulasinghe, A., Thiery, J. P., Maslennikova, A., Zvyagin, A. V., & Warkiani, M. E. (2021) · Theranostics · doi:10.7150/thno.59677 · Cited by 37 · see citing works

Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images

Patkar, S., Chen, A., Basnet, A., Bixby, A., Rajendran, R., Chernet, R., Faso, S., Kumar, P. A., Desai, D., El-Zammar, O., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00765-w · Cited by 41 · see citing works

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Guo, Y., Gao, F., Ahmed, A. R., Rafiq, M., Yu, B., Cong, H., & Shen, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01358h · Cited by 36 · see citing works

Deciphering head and neck cancer microenvironment: Single‐cell and spatial transcriptomics reveals human papillomavirus‐associated differences

Lee, H., Park, S., Yun, J. H., Seo, C., Ahn, J. M., Cha, H., Shin, Y. S., Park, H. R., Lee, D., Roh, J., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29386 · Cited by 36 · see citing works

Ultrasmall silica nanoparticles in translational biomedical research: Overview and outlook

Singh, N., Shi, S., & Goel, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114638 · Cited by 35 · see citing works

Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response

Sadeghirad, H., Monkman, J. H., Tan, C. W., Liu, N., Yunis, J., Donovan, M. L., Moradi, A., Jhaveri, N., Perry, C., Adams, M. N., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05409-y · Cited by 35 · see citing works

Prodrug nanoparticles potentiate tumor chemo-immunometabolic therapy by disturbing oxidative stress

Zhao, H., Li, Y., Shi, H., Niu, M., Li, D., Zhang, Z., Feng, Q., Zhang, Y., & Wang, L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.011 · Cited by 33 · see citing works

Advances in landscape and related therapeutic targets of the prostate tumor microenvironment

Li, D., Xu, W., Chang, Y. E., Xiao, Y., He, Y., & Ren, S. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023092 · Cited by 34 · see citing works

mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends

Gao, Y., Yang, L., Li, Z., Peng, X., & Li, H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00644-3 · Cited by 33 · see citing works

The Road to Precision Nanomedicine: An Insight on Drug Repurposing and Advances in Nanoformulations for Treatment of Cancer

Elmahboub, Y., Albash, R., Ahmed, S., & Salah, S. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03233-1 · Cited by 32 · see citing works

Single-Cell Profiling Reveals Heterogeneity of Primary and Lymph Node Metastatic Tumors and Immune Cell Populations and Discovers Important Prognostic Significance of CCDC43 in Oral Squamous Cell Carcinoma

Wang, Z., Zhang, H., Zhai, Y., Li, F., Shi, X., & Ying, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843322 · Cited by 32 · see citing works

Immunoregulation by resveratrol; implications for normal tissue protection and tumour suppression

Lalani, A. R., Fakhari, F., Radgoudarzi, S., Rastegar‐Pouyani, N., Moloudi, K., Khodamoradi, E., Taeb, S., & Najafi, M. (2023) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13760 · Cited by 32 · see citing works

AFF3 is a novel prognostic biomarker and a potential target for immunotherapy in gastric cancer

Zeng, Y., Zhang, X., Li, F., Wang, Y., & Wei, M. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24437 · Cited by 30 · see citing works

Reprogramming cellular senescence in the tumor microenvironment augments cancer immunotherapy through multifunctional nanocrystals

Wang, Z., Chen, Y., Fang, H., Xiao, K., Wu, Z., Xie, X., Liu, J., Chen, F., He, Y., Wang, L., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp7022 · Cited by 30 · see citing works

The Immune Contexture of Liposarcoma and Its Clinical Implications

Resag, A., Toffanin, G., Benešová, I., Müller, L., Potkrajcic, V., Ozaniak, A., Lischke, R., Bartůňková, J., Rosato, A., Jöhrens, K., et al. (2022) · Cancers · doi:10.3390/cancers14194578 · Cited by 28 · see citing works

NBAtlas: A harmonized single-cell transcriptomic reference atlas of human neuroblastoma tumors

Bonine, N., Zanzani, V., Hemelryk, A. V., Vanneste, B., Zwicker, C., Thoné, T., Roelandt, S., Bekaert, S.-L., Köster, J., Janoueix‐Lerosey, I., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114804 · Cited by 28 · see citing works

Targeting tumor microenvironment for non-small cell lung cancer immunotherapy

Wang, L., Jia, Q., Chu, Q., & Zhu, B. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2022.11.001 · Cited by 26 · see citing works

Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach

Adhikary, S., Pathak, S., Palani, V., Acar, A., Banerjee, A., Al-Dewik, N. I. E., Essa, M. M., Mohammed, S. G. A. A., & Qoronfleh, M. W. (2024) · Biomedicines · doi:10.3390/biomedicines12010217 · Cited by 27 · see citing works

Single Cell RNA-Seq Identifies Immune-Related Prognostic Model and Key Signature-SPP1 in Pancreatic Ductal Adenocarcinoma

Chen, K., Wang, Q., Liu, X., Wang, F., Ma, Y., Zhang, S., Shao, Z., Yang, Y., & Tian, X. (2022) · Genes · doi:10.3390/genes13101760 · Cited by 25 · see citing works

Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy

Chen, H., Sun, T., & Jiang, C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.014 · Cited by 25 · see citing works

High-Throughput immunogenetics for precision medicine in cancer

Agathangelidis, A., Vlachonikola, E., Davi, F., Langerak, A. W., & Chatzidimitriou, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.10.009 · Cited by 24 · see citing works

KIF2C is a Biomarker Correlated With Prognosis and Immunosuppressive Microenvironment in Human Tumors

Zhang, X., Li, Y., Hu, P., Xu, L., & Qiu, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.891408 · Cited by 24 · see citing works

Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer

Zhang, E., Ding, C., Li, S., Aikemu, B., Zhou, X., Fan, X., Sun, J. P., Yang, X. Y., & Zheng, M. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02892-z · Cited by 26 · see citing works

The Sesquiterpene Lactone-Rich Fraction of Inula helenium L. Enhances the Antitumor Effect of Anti-PD-1 Antibody in Colorectal Cancer: Integrative Phytochemical, Transcriptomic, and Experimental Analyses

Chun, J., Park, S., Lee, M., Ha, I. J., & Jeong, M.-K. (2023) · Cancers · doi:10.3390/cancers15030653 · Cited by 23 · see citing works

Advancements in Single‐Cell Proteomics and Mass Spectrometry‐Based Techniques for Unmasking Cellular Diversity in Triple Negative Breast Cancer

Nalla, L. V., Kanukolanu, A., Yeduvaka, M., & Gajula, S. N. R. (2024) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.202400101 · Cited by 23 · see citing works

Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer

Zhang, J., Song, Z., Zhang, Y., Zhang, C., Xue, Q., Zhang, G., & Tan, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1554871 · Cited by 23 · see citing works

Immunotherapeutic targets in non‐small cell lung cancer

Sadeghirad, H., Bahrami, T., Layeghi, S. M., Yousefi, H., Rezaei, M., Hosseini‐Fard, S. R., Radfar, P., Warkiani, M. E., O'Byrne, K. J., & Kulasinghe, A. (2022) · Immunology · doi:10.1111/imm.13562 · Cited by 23 · see citing works

Phytocompounds-based therapeutic approach: Investigating curcumin and green tea extracts on MCF-7 breast cancer cell line

Fawzy, R. M., AbdEl-Aziz, A., Bassiouny, K., & Fayed, A. M. (2024) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2023.100339 · Cited by 23 · see citing works

Pediatric Solid Cancers: Dissecting the Tumor Microenvironment to Improve the Results of Clinical Immunotherapy

Belgiovine, C., Mebelli, K., Raffaele, A., Cicco, M. D., Rotella, J., Pedrazzoli, P., Zecca, M., Riccipetitoni, G., & Comoli, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063225 · Cited by 21 · see citing works

Natural products as promising modulators of breast cancer immunotherapy

Alqathama, A. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410300 · Cited by 21 · see citing works

The Pandora’s box of novel technologies that may revolutionize lung cancer

Sadeghirad, H., Rad, H. S., Shiravand, Y., Radfar, P., Arpon, D. R., Warkiani, M. E., O'Byrne, K. J., & Kulasinghe, A. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.022 · Cited by 21 · see citing works

The main battlefield of mRNA vaccine – Tumor immune microenvironment

Li, X., Ma, S., Gao, T., Mai, Y., Song, Z., & Yang, J. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109367 · Cited by 21 · see citing works

Immune Checkpoint Inhibitors and Lupus Erythematosus

von Eckstaedt, H. V., Singh, A., Reid, P. D., & Trotter, K. C. (2024) · Pharmaceuticals · doi:10.3390/ph17020252 · Cited by 20 · see citing works

Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors

Čierniková, S., Ševčíková, A., Novisedláková, M., & Mego, M. (2024) · Cancers · doi:10.3390/cancers16244271 · Cited by 20 · see citing works

Tailored therapies for triple-negative breast cancer: current landscape and future perceptions

Khan, Y., Rizvi, S., Raza, A., Khan, A., Hussain, M. S., Khan, N. U., Alshammari, S. O., Alshammari, Q. A., Alshammari, A., & Ellakwa, D. E. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03896-4 · Cited by 20 · see citing works

Single-Cell Transcriptome Analysis Reveals Paraspeckles Expression in Osteosarcoma Tissues

Rothzerg, E., Feng, W., Song, D., Li, H., Wei, Q., Fox, A. H., Wood, D., Xu, J., & Liu, Y. (2022) · Cancer Informatics · doi:10.1177/11769351221140101 · Cited by 20 · see citing works

Targeting Farnesoid X Receptor in Tumor and the Tumor Microenvironment: Implication for Therapy

Nenkov, M., Shi, Y. H., Ma, Y., Gaßler, N., & Chen, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010006 · Cited by 22 · see citing works

Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer

Qu, F., Wu, S., & Yu, W. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s500281 · Cited by 20 · see citing works

Immune checkpoint inhibitors and immunosuppressive tumor microenvironment: current challenges and strategies to overcome resistance

Gill, G. S., Kharb, S., Goyal, G., Das, P., Kurdia, K. C., Dhar, R., & Karmakar, S. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2504906 · Cited by 19 · see citing works

Advances in Stimuli‐Responsive Release Strategies for Sonosensitizers in Synergistic Sonodynamic Immunotherapy against Tumors

Ding, R., Yang, H., Wang, J., Liu, Y., Mu, S., Wang, D., & Li, J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502183 · Cited by 19 · see citing works

Carrier-Free Nanomedicine for Cancer Immunotherapy

Fu, Y., Bian, X., Li, P., Huang, Y., & Li, C. (2022) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2022.3315 · Cited by 19 · see citing works

CircRNA Regulation of T Cells in Cancer: Unraveling Potential Targets

Li, Z., Yin, S., Yang, K., Zhang, B., Wu, X., Zhang, M., & Gao, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126383 · Cited by 19 · see citing works

Identification of hepatocellular carcinoma-related genes associated with macrophage differentiation based on bioinformatics analyses

Cao, J., Zhang, C., Jiang, G., Jin, S., Wang, Q., Wang, A., & Bai, D. (2020) · Bioengineered · doi:10.1080/21655979.2020.1868119 · Cited by 19 · see citing works

Research advances on the immune research and prospect of immunotherapy in pituitary adenomas

Nie, D., Fang, Q., Li, B., Cheng, J., Li, C., Gui, S., Zhang, Y., & Zhao, P. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02272-9 · Cited by 18 · see citing works

Spatial profiling technologies and applications for brain cancers

Croft, P. K., Sadeghirad, H., Gasper, H. M., O'Byrne, K. J., Lakhani, S. R., & Kulasinghe, A. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1900735 · Cited by 17 · see citing works

The Aging-Related Prognostic Signature Reveals the Landscape of the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma

Chen, F., Gong, X., Meng, X., Feng, Y., Wu, J., Yu, C., & Li, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.857994 · Cited by 17 · see citing works

Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma

Li, H., Zu, X., Hu, J., Xiao, Z., Cai, Z., Gao, N., & Chen, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964393 · Cited by 17 · see citing works

Crosstalk between Tumor-Associated Macrophages and MicroRNAs: A Key Role in Tumor Microenvironment

Zhou, X., Chen, B., Zhang, Z., Huang, Y., Li, J., Wei, Q., Cao, D., & Ai, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113258 · Cited by 17 · see citing works

Reprogramming tumor-associated macrophages using exosomes from M1 macrophages

Mahmoudi, M., Taghavi-Farahabadi, M., Hashemi, S. M., Mousavizadeh‬, K., Rezaei, N., & Mojtabavi, N. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150697 · Cited by 17 · see citing works

Battlegrounds of treatment resistance: decoding the tumor microenvironment

Bayat, M., & Nahand, J. S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04055-5 · Cited by 16 · see citing works

Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems

Perra, M., Castangia, I., Aroffu, M., Fulgheri, F., Rached, R. A., Manca, M. L., Cortés, H., Prado-Audelo, M. L. D., Nomura-Contreras, C. A., Romero‐Montero, A., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-01820-z · Cited by 16 · see citing works

Immune-related gene signature associates with immune landscape and predicts prognosis accurately in patients with Wilms tumour

Tian, X., Xiang, B., Jin, L., Mi, T., Wang, J.-K., Zhanghuang, C., Zhang, Z., Chen, M., Shi, Q., Liu, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.920666 · Cited by 16 · see citing works

CD8+ Cell Density Gradient across the Tumor Epithelium–Stromal Interface of Non-Muscle Invasive Papillary Urothelial Carcinoma Predicts Recurrence-Free Survival after BCG Immunotherapy

Drachneris, J., Rasmusson, A., Morkūnas, M., Fabijonavicius, M., Čekauskas, A., Jankevičius, F., & Laurinavičius, A. (2023) · Cancers · doi:10.3390/cancers15041205 · Cited by 15 · see citing works

Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment

Wang, P., Wang, X., Man, C., Gong, D., & Fan, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200619 · Cited by 16 · see citing works

AI-based tumor-infiltrating lymphocyte scoring system for assessing HCC prognosis in patients undergoing liver resection

Chen, Z., Xie, T., Chen, S., Li, Z., Yao, S., Lü, X., He, W., Tang, C., Yang, D., Li, S., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101270 · Cited by 15 · see citing works

The latest applications of exosome-mediated drug delivery in anticancer therapies

Wen, Z., Zhang, W., & Wu, W. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114500 · Cited by 15 · see citing works

Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases

Yang, G., Xing, L., & Sun, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.852811 · Cited by 15 · see citing works

The evolving landscape of predictive biomarkers in immuno‐oncology with a focus on spatial technologies

Sadeghirad, H., Bazaz, S. R., Monkman, J. H., Warkiani, M. E., Rezaei, N., O'Byrne, K. J., & Kulasinghe, A. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1215 · Cited by 38 · see citing works

Insights into the Mechanisms of Immune‐Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor Microenvironment

Zhang, Y.-Y., & Liu, Z.-H. (2025) · Advancement of science · doi:10.1002/advs.202508692 · Cited by 17 · see citing works

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses

Oliver, A. J., Lau, P. K. H., Unsworth, A., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 165 · see citing works

Role of tumor microenvironment in regulator of tumor progression and immunotherapy

周平平 (2026) · Discover Oncology · doi:10.1007/s12672-026-04421-6 · Cited by 3 · see citing works

Research Progress on the Regulation of Tumor Microenvironment in Immunotherapy

Ren, J., Xie, W., & Zhang, H. (2025) · Journal of Contemporary Medical Practice · doi:10.53469/jcmp.2025.07(04).51